Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tetra Bio Pharma Inc TBPMQ

Healthcare Cannabis
Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to... see more

Recent & Breaking News (GREY:TBPMQ)

Tetra Bio-Pharma Responds to Shareholders

GlobeNewswire December 4, 2018

Tetra Bio-Pharma Convenes First National Medical Advisory Board

GlobeNewswire December 4, 2018

Tetra Natural Health Will Deliver 20 containers of Hemp Energy Drink to Meet Consumer Demand

GlobeNewswire December 3, 2018

Tetra Bio-Pharma Closes Financing With Aphria Inc.

GlobeNewswire November 30, 2018

Tetra Bio-Pharma Bolsters Intellectual Property Position and Product Pipeline

GlobeNewswire November 27, 2018

Tetra Bio-Pharma’s Dr. Chamberland Goes to Washington!

GlobeNewswire November 26, 2018

Tetra Bio-Pharma Seeks Solutions for Second Hand Smoke From Cannabis

GlobeNewswire November 22, 2018

Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.

GlobeNewswire November 20, 2018

Pilot Study to Investigate a Cannabinoid Derived Drug in Dogs 

GlobeNewswire November 15, 2018

Tetra Bio-Pharma Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs

GlobeNewswire November 13, 2018

Tetra Bio-Pharma Enters into Non-Binding Proposal to Acquire Panag Pharma Inc.

GlobeNewswire November 6, 2018

Tetra Natural Health Signs Exclusive Agreement for the Distribution of their Hemp Energy Drink in Canada and the USA

GlobeNewswire November 1, 2018

Tetra Bio-Pharma Obtains Health Canada Approval to Conduct a Phase 1 Pharmacokinetic & Safety Study Using Vaporized Version of PPP001

GlobeNewswire November 1, 2018

Tetra Bio-Pharma Appoints Richard Giguère Chief Executive Officer of Tetra Natural Health   

GlobeNewswire October 24, 2018

Statement from Tetra Bio-Pharma on the legalization of recreational cannabis

Canada NewsWire October 16, 2018

Media Advisory - Dr. Chamberland, Expert Spokesperson available to discuss legalization of recreational cannabis

Canada NewsWire October 15, 2018

Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer

GlobeNewswire October 15, 2018

Tetra Bio-Pharma’s PPP002 on Track After Type C Meeting with FDA

GlobeNewswire October 11, 2018

Tetra Bio-Pharma Moves PPP001 Closer to Commercial Manufacturing with the Issuance of a Drug Establishment License to Ford’s Pharmacy

GlobeNewswire October 3, 2018

Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA

GlobeNewswire September 27, 2018